Table 4.
Univariable Cox analysis showing the association between study variables at baseline and achievement of endoscopic remission.
| Variable | HR | 95% CI | P value |
|---|---|---|---|
| Age at diagnosis (OR per year) | 0.99 | 0.97-1.01 | .41 |
| Age at ustekinumab initiation (OR per year) | 0.99 | 0.97-1.02 | .61 |
| Disease duration (OR per year) | 1.01 | 0.97-1.05 | .63 |
| Sex | |||
| Female (ref) | — | — | — |
| Male | 0.66 | 0.34-1.31 | .24 |
| Race | |||
| Not NHW (ref) | — | — | — |
| NHW | 1.56 | 0.61-4.04 | .36 |
| Smoking status | |||
| Never (ref) | — | — | — |
| Past | 0.82 | 0.38-1.73 | .6 |
| History of hospitalizations | |||
| No (ref) | — | — | — |
| Yes | 0.55 | 0.26-1.16 | .12 |
| Body mass index (OR per unit) | |||
| Partial Mayo score at baseline (OR per unit) | 0.99 | 0.96-1.04 | .97 |
| History of extraintestinal manifestations | 0.88 | 0.72-1.07 | .203 |
| No (ref) | — | — | — |
| Yes | 0.99 | 0.51-1.95 | .99 |
| Previous us of aminosalicylates | |||
| No (ref) | — | — | — |
| Yes | 1.1 | 0.42-2.89 | .84 |
| Previous use of methotrexate | |||
| No (ref) | — | — | — |
| Yes | 0.65 | 0.29-1.43 | 0.28 |
| Previous use of thiopurine | |||
| No (ref) | — | — | — |
| Yes | 1.03 | 0.54-1.97 | .93 |
| Disease extent | |||
| E1 (ref) | — | — | — |
| E2 | 0.53 | 0.06-4.45 | .56 |
| E3 | 0.65 | 0.09-4.86 | .67 |
| Concomitant use of corticosteroids | |||
| No (ref) | — | — | — |
| Yes | 0.71 | 0.37-1.35 | .29 |
| Concomitant use of immunomodulators | |||
| No (ref) | — | — | — |
| Yes | 0.39 | 0.09-1.63 | .19 |
| Concomitant use of aminosalicylates | |||
| No (ref) | — | — | — |
| Yes | 2.46 | 0.99-6.09 | .05 |
| Exposure to anti-TNF only | |||
| No (ref) | — | — | — |
| Yes | 1.38 | 0.71-2.70 | .34 |
| Exposure to anti-TNF and vedolizumab only | |||
| No (ref) | — | — | — |
| Yes | 0.49 | 0.20-1.17 | .1 |
| Exposure to vedolizumab only | |||
| No (ref) | — | — | — |
| Yes | 2.2 | 0.91-5.31 | .07 |
| Exposure to anti-TNF, vedolizumab, and tofacitinib | |||
| No (ref) | — | — | — |
| Yes | 0.42 | 0.15-1.17 | .09 |
| Baseline C-reactive protein (OR per mg/dL) | 0.93 | 0.86-0.99 | .04a |
| Baseline albumin (OR per mg/dL) | 2.5 | 1.13-5.52 | .02a |
None of the patients that qualified for the analysis were active smokers.
Abbreviations: CI, confidence interval; HR, hazard ratio; NHW, non-Hispanic White; OR, odds ratio; TNF, tumor necrosis factor.
aStatistically significant.